

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 20 of 25 returned.****1. Document ID: US 20030203930 A1**

L2: Entry 1 of 25

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203930

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030203930 A1

TITLE: Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chaudry, Imtiaz	Napa	CA	US	
Banerjee, Partha	San Ramon	CA	US	

US-CL-CURRENT: 514/291; 128/200.23, 424/45

ABSTRACT:

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Func
Draw Desc	Image										

2. Document ID: US 20030191151 A1

L2: Entry 2 of 25

File: PGPB

Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030191151

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030191151 A1

TITLE: Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chaudry, Imtiaz	Napa	CA	US	
Banerjee, Partha	San Ramon	CA	US	

US-CL-CURRENT: 514/304; 514/651

ABSTRACT:

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Foot
Draw Data	Image										

3. Document ID: US 20030180317 A1

L2: Entry 3 of 25

File: PGPB

Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180317

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030180317 A1

TITLE: Moraxella catarrhalis BASB034 polypeptides and used thereof

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruelle, Jean-Louis	Limal		BE	

US-CL-CURRENT: 424/190.1; 435/252.3, 435/320.1, 435/69.3, 530/350, 536/23.7

ABSTRACT:

Provided are Moraxella catarrhalis BASB034 polypeptides and immunogenic fragments of BASB034 polypeptides. Preferably, the immunogenic fragments have at least 15 amino acids that match an aligned contiguous segment of SEQ ID NOs:2, 4, 6 or 8. The immunogenic fragments, when administered to a subject in a suitable composition (which can include an adjuvant, or a suitable carrier coupled to the fragment) raise an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:2, 4, 6 or 8. The invention further provides immunogenic compositions containing BASB034 polypeptides and immunogenic fragments thereof, and a pharmaceutically acceptable carrier. Also provided are fusion proteins that contain BASB034 polypeptides and immunogenic fragments thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Foot
Draw Data	Image										

4. Document ID: US 20030161835 A1

L2: Entry 4 of 25

File: PGPB

Aug 28, 2003

PGPUB-DOCUMENT-NUMBER: 20030161835
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030161835 A1

TITLE: Polypeptides from moraxella (branhamella) catarrhalis

PUBLICATION-DATE: August 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ruelle, Jean-Louis	Limal		BE	

US-CL-CURRENT: 424/184.1; 530/350

ABSTRACT:

The invention provides BASB011 polypeptides and polynucleotides encoding BASB011 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	End
Draw Desc	Image									

5. Document ID: US 20030091974 A1

L2: Entry 5 of 25

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030091974
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030091974 A1

TITLE: Method for screening compounds capable of depleting mast cells

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Moussy, Alain	Paris	MA	FR	
Kinet, Jean-Pierre	Lexington		US	

US-CL-CURRENT: 435/4; 435/7.21

ABSTRACT:

A method of identifying compounds that deplete mast cells without depleting other related cells is described. The invention further relates to compounds identified by the screening method and their uses in treating diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	End
Draw Desc	Image									

6. Document ID: US 20020150537 A1

L2: Entry 6 of 25

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150537
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150537 A1

TITLE: Method for assessing food allergenicity

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Val, Gregorio del	San Diego	CA	US	
Yee, Boihon C.	Walnut Creek	CA	US	
Jung, Hye Rim	Alameda	CA	US	
Buchanan, Bob	Berkeley	CA	US	
Frick, Oscar L.	San Francisco	CA	US	

US-CL-CURRENT: 424/9.2; 800/3

ABSTRACT:

A method for testing the allergenicity of a heterologous protein produced by a plant or animal that has been genetically modified to produce that protein is disclosed. The method includes the steps of: (a) sensitizing a newborn dog from an atopic dog colony with a first extract prepared from tissue of the genetically modified plant or animal and containing a mixture of plant or animal proteins and the heterologous protein, by injecting or feeding the extract into the newborn dog; (b) after a period sufficient to allow the dog to establish an immune response to the sensitizing extract, challenging the dog with the extract; (c) observing the degree of allergic response provoked; (d) if a detectable skin reaction is observed, comparing the degree of skin reaction observed with that observed by carrying out steps (a)-(c) above, but where the sensitizing step (a) or applying step (b) is carried out with a second plant or animal extract containing substantially the same proteins as the first extract but lacking the heterologous protein; and (e) if the degree of skin reaction at (c) is greater than that observed by carrying out steps (a)-(c) in accordance with step (d), identifying the heterologous protein as a potential allergen in humans. Also disclosed is a dog for use in testing a biological substance for allergenicity in humans, and compositions useful in practicing the method.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMOC
Draw Page	Image									

7. Document ID: US 20020137117 A1

L2: Entry 7 of 25

File: PGPB

Sep 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020137117
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020137117 A1

TITLE: Rapid diagnostic method for distinguishing allergies and infections and nasal secretion collection unit

PUBLICATION-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Small, Parker	Gainesville	FL	US	
Huang, Shih-Wen	Gainesville	FL	US	
Kudla, Ronald	Gainesville	FL	US	

US-CL-CURRENT: 435/19

ABSTRACT:

A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, leukocyte esterase activity, and eosinophil content or other measure of a substance found in allergic secretions, such as TAME esterase, of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and TAME esterase activity. The invention further provides a novel means for collecting nasal secretions to facilitate differential diagnosis of sinusitis, upper respiratory tract viral infection and allergic rhinitis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Full
Draw Desc	Image									

8. Document ID: US 20020086287 A1

L2: Entry 8 of 25

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086287

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086287 A1

TITLE: Rapid diagnostic method for distinguishing allergies and infections and nasal secretion collection unit

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Small, Parker	Gainesville	FL	US	
Huang, Shih-Wen	Gainesville	FL	US	
Kudla, Ronald	Gainesville	FL	US	

US-CL-CURRENT: 435/5; 435/19

ABSTRACT:

A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, leukocyte esterase activity, and eosinophil content or other measure of a substance found in allergic secretions, such as TAME esterase, of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic,

bacterial and viral conditions, based on pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and TAME esterase activity. The invention further provides a novel means for collecting nasal secretions to facilitate differential diagnosis of sinusitis, upper respiratory tract viral infection and allergic rhinitis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Image
Draw Desc	Image									

9. Document ID: US 20020086286 A1

L2: Entry 9 of 25

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086286
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086286 A1

TITLE: Rapid diagnostic method for distinguishing allergies and infections and nasal secretion collection unit

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Small, Parker	Gainesville	FL	US	
Huang, Shih-Wen	Gainesville	FL	US	
Kudla, Ronald	Gainesville	FL	US	

US-CL-CURRENT: 435/5; 435/19

ABSTRACT:

A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, leukocyte esterase activity, and eosinophil content or other measure of a substance found in allergic secretions, such as TAME esterase, of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and TAME esterase activity. The invention further provides a novel means for collecting nasal secretions to facilitate differential diagnosis of sinusitis, upper respiratory tract viral infection and allergic rhinitis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Image
Draw Desc	Image									

10. Document ID: US 20020081575 A1

L2: Entry 10 of 25

File: PGPB

Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081575
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081575 A1

TITLE: Rapid diagnostic method for distinguishing allergies and infections and nasal secretion collection unit

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Small, Parker	Gainesville	FL	US	
Huang, Shih-Wen	Gainesville	FL	US	
Kudla, Ronald	Gainesville	FL	US	

US-CL-CURRENT: 435/5; 435/19

ABSTRACT:

A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, leukocyte esterase activity, and eosinophil content or other measure of a substance found in allergic secretions, such as TAME esterase, of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and TAME esterase activity. The invention further provides a novel means for collecting nasal secretions to facilitate differential diagnosis of sinusitis, upper respiratory tract viral infection and allergic rhinitis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Full
Draw Desc	Image									

11. Document ID: US 20020061281 A1

L2: Entry 11 of 25

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061281

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061281 A1

TITLE: Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Osbakken, Robert S.	Camarillo	CA	US	
Hale, Mary Anne	Woodland Hills	CA	US	
Leivo, Frederick T.	Carpinteria	CA	US	
Munk, James D.	Camarillo	CA	US	

US-CL-CURRENT: 424/43

ABSTRACT:

Pharmaceutical compositions are described that comprise one or more active

ingredients selected from the group consisting of an anti-infective agent, anti-inflammatory agent, anti-mucolytic agent, antihistamine, an antiseptic, and antibiotic combinations or combinations of others of these classes of ingredients, and particularly to compositions formulated as a solution or suspension in a unit dose for aerosol administration to treat chronic sinusitis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print
Draw Desc	Image									

12. Document ID: US 6649171 B1

L2: Entry 12 of 25

File: USPT

Nov 18, 2003

US-PAT-NO: 6649171

DOCUMENT-IDENTIFIER: US 6649171 B1

TITLE: *Moraxella catarrhalis* polynucleotides and polypeptides

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thonnard; Joelle	Gembloux			BE

US-CL-CURRENT: 424/251.1; 424/185.1, 424/190.1, 424/192.1, 424/197.11, 424/234.1, 530/301, 530/326, 530/350

ABSTRACT:

The invention provides BASB021 polypeptides and polynucleotides encoding BASB021 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

8 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print
Draw Desc	Image									

13. Document ID: US 6632842 B2

L2: Entry 13 of 25

File: USPT

Oct 14, 2003

US-PAT-NO: 6632842

DOCUMENT-IDENTIFIER: US 6632842 B2

TITLE: Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chaudry; Imtiaz	Napa	CA		
Banerjee; Partha	San Ramon	CA		

US-CL-CURRENT: 514/651; 424/45, 424/46, 514/304, 514/649

ABSTRACT:

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

3 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Find
Draw Desc	Image									

14. Document ID: US 6627728 B1

L2: Entry 14 of 25

File: USPT

Sep 30, 2003

US-PAT-NO: 6627728

DOCUMENT-IDENTIFIER: US 6627728 B1

TITLE: Compounds from moraxella catarrhalis

DATE-ISSUED: September 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thonnard; Joelle	Gembloux			BE

US-CL-CURRENT: 530/300; 424/130.1, 424/134.1, 424/150.1, 424/185.1, 424/251.1, 435/7.2, 435/7.32, 530/387.3, 530/388.2

ABSTRACT:

The invention provides BASB010 polypeptides and polynucleotides encoding BASB010 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

6 Claims, 19 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Find
Draw Desc	Image									

15. Document ID: US 6613335 B1

L2: Entry 15 of 25

File: USPT

Sep 2, 2003

US-PAT-NO: 6613335

DOCUMENT-IDENTIFIER: US 6613335 B1

TITLE: Polypeptides from moraxella (branhamella) catarrhalis

DATE-ISSUED: September 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruelle; Jean-Louis	Limal			BE

US-CL-CURRENT: 424/251.1; 424/234.1, 435/252.3, 435/320.1, 435/69.3

ABSTRACT:

Provided are BASB011 polypeptides and polynucleotides encoding BASB011 polypeptide from Moraxella catarrhalis. Also provided are immunogenic uses.

33 Claims, 23 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Home
Draw Desc	Image									

16. Document ID: US 6600013 B1

L2: Entry 16 of 25

File: USPT

Jul 29, 2003

US-PAT-NO: 6600013

DOCUMENT-IDENTIFIER: US 6600013 B1

TITLE: Moraxella catarrhalis BASB034 polypeptides and uses thereof

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruelle; Jean-Louis	Limal			BE

US-CL-CURRENT: 530/300; 424/130.1, 424/134.1, 424/150.1, 435/7.2, 530/387.2, 530/387.3

ABSTRACT:

Provided are Moraxella catarrhalis BASB034 polypeptides and immunogenic fragments of BASB034 polypeptides. Preferably, the immunogenic fragments have at least 15 amino acids that match an aligned contiguous segment of SEQ ID NOS:2, 4, 6 or 8. The immunogenic fragments, when administered to a subject in a suitable composition (which can include an adjuvant, or a suitable carrier coupled to the fragment) raise an immune response that recognizes a polypeptide having the sequence of SEQ ID NOS:2, 4, 6 or 8. The invention further provides immunogenic compositions containing BASB034 polypeptides and immunogenic fragments thereof, and a pharmaceutically acceptable carrier. Also provided are fusion proteins that contain BASB034 polypeptides and

immunogenic fragments thereof.

10 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Final
Draw Desc	Image									

17. Document ID: US 6599879 B1

L2: Entry 17 of 25

File: USPT

Jul 29, 2003

US-PAT-NO: 6599879
DOCUMENT-IDENTIFIER: US 6599879 B1

TITLE: Therapeutic uses of keratinocyte growth factor-2

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jimenez; Pablo	Ellicott	MD		
Rampy; Mark A.	Montgomery Village	MD		
Mendrick; Donna	Mount Airy	MD		
Russell; Deborah	Laytonsville	MD		
Louie; Arthur	Potomac	MD		

US-CL-CURRENT: 514/12; 514/2, 530/399

ABSTRACT:

The present invention relates to the administration of Keratinocyte Growth Factor-2 (KGF-2) to stimulate proliferation of platelets and to increase levels of fibrinogen, albumin, globulin and total serum protein. Further, the present invention relates to administering KGF-2 to protect or treat the bladder and prostate. Moreover, the present invention relates to administering KGF-2 to stimulate growth of nasal, oral, and esophageal mucosa, lacrimal glands, salivary glands and Goblet cells.

8 Claims, 73 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 63

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Final
Draw Desc	Image									

18. Document ID: US 6551791 B1

L2: Entry 18 of 25

File: USPT

Apr 22, 2003

US-PAT-NO: 6551791
DOCUMENT-IDENTIFIER: US 6551791 B1

TITLE: Rapid diagnostic method for distinguishing allergies and infections and nasal

secretion collection unit

DATE-ISSUED: April 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Small; Parker	Gainesville	FL		
Huang; Shih-Wen	Gainesville	FL		
Kudla; Ronald	Gainesville	FL		

US-CL-CURRENT: 435/19; 435/34, 436/811

ABSTRACT:

A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, leukocyte esterase activity, and eosinophil content or other measure of a substance found in allergic secretions, such as TAME esterase, of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and TAME esterase activity. The invention further provides a novel means for collecting nasal secretions to facilitate differential diagnosis of sinusitis, upper respiratory tract viral infection and allergic rhinitis.

8 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Print
Draw Desc	Image									

19. Document ID: US 5631267 A

L2: Entry 19 of 25

File: USPT

May 20, 1997

US-PAT-NO: 5631267

DOCUMENT-IDENTIFIER: US 5631267 A

TITLE: Method for the treatment of eosinophil-associated diseases by administration of topical anesthetics

DATE-ISSUED: May 20, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gleich; Gerald J.	Rochester	MN		
Ohnishi; Tsukasa	Tokyo			JP
Hunt; Loren W.	Rochester	MN		

US-CL-CURRENT: 514/312; 514/317, 514/330, 514/535, 514/540, 514/626, 514/826, 514/914

ABSTRACT:

A therapeutic method is provided to treat eosinophil-associated hypersensitivity

diseases, such as bronchial asthma, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

15 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Find
Draw Desc	Image									

20. Document ID: US 5510339 A

L2: Entry 20 of 25

File: USPT

Apr 23, 1996

US-PAT-NO: 5510339

DOCUMENT-IDENTIFIER: US 5510339 A

TITLE: Method for the treatment of bronchial asthma by administration of topical anesthetics

DATE-ISSUED: April 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gleich; Gerald J.	Rochester	MN		
Ohnishi; Tsukasa	Tokyo			JP
Hunt; Loren W.	Rochester	MN		

US-CL-CURRENT: 514/171; 514/626, 514/826

ABSTRACT:

A therapeutic method is provided to treat eosinophil-associated hypersensitivity diseases, such as bronchial asthma, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

10 Claims, 11 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Find
Draw Desc	Image									

Generate Collection

Print

Term	Documents
KIT	126181
KITS	42350
(1 AND KIT).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	25
(L1 AND KIT).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	25

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

1/34/2 (Item 1 from file: 351)

013834942

WPI Acc No: 2001-319154/200134

Detecting proteins (e.g. immunoglobulin E) in nasal secretions, useful for diagnosing allergy comprises taking sample on adsorbent material

Patent Assignee: BLOCH-MICHEL E (BLOC-I); DE LUCA H (DLUC-I); BLOCH M E (BLOC-I); SUSINI E (SUSI-I)

Inventor: BLOCH-MICHEL E; DE LUCA H; BLOCH M E; SUSINI E

Number of Countries: 025 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 1096258	A1	20010502	EP 2000403010	A	20001030	200134 B
FR 2800469	A1	20010504	FR 9913568	A	19991029	200134

Priority Applications (No Type Date): FR 9913568 A 19991029

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

EP 1096258 A1 F 10 G01N-033/68

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI

FR 2800469 A1 G01N-033/68

Abstract (Basic): EP 1096258 A1

NOVELTY - Method for detecting a protein or a glycoprotein (I) comprises:

- (i) collecting nasal secretions on adsorbent material (A), by placing this in contact with the nasal mucosa; and
- (ii) detecting (I), in (A), by an immunological reaction.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for quantifying (I) in which (A) is contacted with nasal mucosa until equilibrium is reached between the amount of (I) adsorbed and the concentration of (I) in the secretions;

(2) a method for diagnosis, monitoring and characterization of allergy by detecting/quantifying immunoglobulin E (IgE) in nasal secretions; and

(3) a kit for the new process comprising a tube coated with anti-IgE; solution of enzyme-labeled anti-IgE, and optionally adsorbent material, impregnated with standard IgE, wash solutions and/or chromogenic substrate for the enzyme.

USE - The method is especially used to detect (i) immunoglobulin E (IgE), especially total IgE or (ii) a marker of an inflammatory or pathological condition (claimed). Particularly it is used to diagnose, monitor or characterize an allergy (claimed), whether local or generalized, e.g. asthma, eczema, rhinitis or allergic sinusitis. It can be used with humans (including children) or animals.

ADVANTAGE - The process is a simple and efficient way of collecting a sample and provides sensitive determination of immunoglobulin E and thus reliable information about the patient's allergic status. Several (glyco)proteins may be determined simultaneously.

pp: 10 DwgNo 0/0

Technology Focus:

TECHNOLOGY FOCUS - BIOLOGY - Preferred process: In method (1), the amount of (I) adsorbed by (A) is measured and compared with a standard curve to establish the absolute amount of (I) in the secretions. Detection/quantification is by conventional immunoassays, using appropriate, optionally labeled, antigens and antibodies, most

preferably by a sandwich-type enzyme-linked immunosorbent assay (ELISA). In this case (A) is treated with two antibodies; one free in solution and labeled, the other immobilized on a solid phase. The antibodies may be mono- or poly-clonal; a preferred label is peroxidase and a suitable color-former is o-phenylene diamine.

Preferred materials: (A) is made, at least partly, from a polymer and/or natural or synthetic macromolecule, most preferably it is cellulosic. (A) particularly consists of a support, e.g. a tablet or disk, surgical sponge etc., most preferably a paper strip about 5 x 55 mm, which is placed manually in the nostril for 1-3 min to allow equilibrium to be reached.

Derwent Class: B04; D16; S03

International Patent Class (Main): G01N-033/68

Derwent WPI (Dialog® File 351). (c) 2003 Thomson Derwent. All rights reserved

© 2003 Dialog, a Thomson business